Crossmark

Year-round efficacy of a single treatment of fluralaner injectable suspension (Bravecto QuantumTM) against repeated infestations with Ixodes holocyclus in dogs

Crossref DOI link: https://doi.org/10.1186/s13071-023-05951-6

Published Online: 2023-10-20

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Fisara, Petr

Guerino, Frank
License Information

Text and Data Mining valid from 2023-10-20

Version of Record valid from 2023-10-20
More Information

Article History

Received: 18 May 2023

Accepted: 28 August 2023

First Online: 20 October 2023

Declarations

:

: For Study 1, Animal Ethics Committee approval was obtained prior to the commencement of the study from the Wongaburra Research Centre Animal Ethics Committee. The study was covered by small trial permit no. PER 7250 ‘Permit to allow the conduct of small-scale trials with agvet chemicals’ issued by the Australian Pesticides and Veterinary Medicines Authority (APVMA). An Animal Research Authority and a Certificate of Approval to provide ethics clearance were obtained for Study 2 from the New South Wales Department of Primary Industries Secretary’s Animal Care and Ethics Committee (SACEC) (TRIM 20/13 (20).

: Not applicable.

: Petr Fisara is an employee of MSD Animal Health and Frank Guerino is an employee of Merck Animal Health, Rahway, NJ, USA.

Document is current

Any future updates will be listed below